<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Matricelf Ltd. — News on 6ix</title>
<link>https://6ix.com/company/matricelf-ltd</link>
<description>Latest news and press releases for Matricelf Ltd. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 30 Mar 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/matricelf-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836280578dffbe2df1443f7.webp</url>
<title>Matricelf Ltd.</title>
<link>https://6ix.com/company/matricelf-ltd</link>
</image>
<item>
<title>Matricelf Enters Strategic Collaboration with Japan's CiRA Foundation to Advance Next-Generation Regenerative Manufacturing</title>
<link>https://6ix.com/company/matricelf-ltd/news/matricelf-enters-strategic-collaboration-with-japans-cira-foundation-to-advance-next-generation-regenerative-manufacturing</link>
<guid isPermaLink="true">https://6ix.com/company/matricelf-ltd/news/matricelf-enters-strategic-collaboration-with-japans-cira-foundation-to-advance-next-generation-regenerative-manufacturing</guid>
<pubDate>Mon, 30 Mar 2026 11:00:00 GMT</pubDate>
<description>Matricelf Ltd. (TASE: MTLF), a biotechnology company developing a novel autologous engineered neural tissue therapy for patients with spinal cord injury, today announced it has entered into a Collaborative Research Agreement with the CiRA Foundation, a global leader in induced pluripotent stem cell (iPSC) research and regenerative medicine.</description>
</item>
<item>
<title>Matricelf (TASE: MTLF) Enters Strategic Collaboration with Sheba Medical Center to Advance First in Human Clinical Program in Spinal Cord Injury</title>
<link>https://6ix.com/company/matricelf-ltd/news/matricelf-tase-mtlf-enters-strategic-collaboration-with-sheba-medical-center-to-advance-first-in-human-clinical-program-in-spinal-cord-injury</link>
<guid isPermaLink="true">https://6ix.com/company/matricelf-ltd/news/matricelf-tase-mtlf-enters-strategic-collaboration-with-sheba-medical-center-to-advance-first-in-human-clinical-program-in-spinal-cord-injury</guid>
<pubDate>Tue, 24 Mar 2026 12:08:00 GMT</pubDate>
<description>Matricelf Ltd. (TASE: MTLF), a regenerative medicine company developing autologous engineered neural tissue therapies, today announced a strategic collaboration with Sheba Medical Center, Tel Hashomer, ranked 7th globally by Newsweek, to support the execution of its first in human clinical trial in spinal cord injury.</description>
</item>
<item>
<title>Matricelf Ltd. (TASE: MTLF) Reports Positive RNA Sequencing Results Demonstrating Promising Safety Profile of Its Personalized Spinal Cord Implant</title>
<link>https://6ix.com/company/matricelf-ltd/news/matricelf-ltd-tase-mtlf-reports-positive-rna-sequencing-results-demonstrating-promising-safety-profile-of-its-personalized-spinal-cord-implant-7</link>
<guid isPermaLink="true">https://6ix.com/company/matricelf-ltd/news/matricelf-ltd-tase-mtlf-reports-positive-rna-sequencing-results-demonstrating-promising-safety-profile-of-its-personalized-spinal-cord-implant-7</guid>
<pubDate>Wed, 04 Mar 2026 12:00:00 GMT</pubDate>
<description>Matricelf Ltd. (TASE: MTLF), a regenerative medicine company developing personalized engineered neural tissue implants for the treatment of spinal cord injury, today announced positive results from advanced RNA sequencing analyses of its human tissue implant, supporting key safety characteristics required for progression toward clinical trials.</description>
</item>
<item>
<title>Matricelf Ltd. (TASE: MTLF) Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy</title>
<link>https://6ix.com/company/matricelf-ltd/news/matricelf-ltd-tase-mtlf-signs-mou-to-establish-subsidiary-for-commercialization-of-parkinsons-disease-therapy</link>
<guid isPermaLink="true">https://6ix.com/company/matricelf-ltd/news/matricelf-ltd-tase-mtlf-signs-mou-to-establish-subsidiary-for-commercialization-of-parkinsons-disease-therapy</guid>
<pubDate>Tue, 03 Mar 2026 12:00:00 GMT</pubDate>
<description>Matricelf Ltd. (TASE: MTLF), a biotechnology company developing autologous engineered tissue therapies, today announced that it has signed a Memorandum of Understanding, subject to the execution of a definitive agreement and satisfaction of customary closing conditions, to establish a dedicated subsidiary for the research, development, and commercialization of the Company's technology for the treatment of Parkinson's disease.</description>
</item>
<item>
<title>Matricelf Named Most Innovative Company of 2026 at Advanced Therapies Week in San Diego</title>
<link>https://6ix.com/company/matricelf-ltd/news/matricelf-named-most-innovative-company-of-2026-at-advanced-therapies-week-in-san-diego</link>
<guid isPermaLink="true">https://6ix.com/company/matricelf-ltd/news/matricelf-named-most-innovative-company-of-2026-at-advanced-therapies-week-in-san-diego</guid>
<pubDate>Mon, 02 Mar 2026 12:00:00 GMT</pubDate>
<description>Matricelf Ltd. (TASE: MTLF), a biotechnology company developing personalized regenerative therapies, today announced that it was awarded 1st place at the prestigious Innovation Exchange Award and named the Most Innovative Company of 2026 at Advanced Therapies Week (ATW26), held in San Diego, California.</description>
</item>
<item>
<title>Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board</title>
<link>https://6ix.com/company/matricelf-ltd/news/matricelf-ltd-tase-mtlf-appoints-ron-mayron-as-chairman-of-the-board</link>
<guid isPermaLink="true">https://6ix.com/company/matricelf-ltd/news/matricelf-ltd-tase-mtlf-appoints-ron-mayron-as-chairman-of-the-board</guid>
<pubDate>Fri, 27 Feb 2026 12:00:00 GMT</pubDate>
<description>Matricelf Ltd. (TASE: MTLF), a biotechnology company developing autologous engineered tissue therapies, today announced the appointment of Mr. Ron Mayron as Active Chairman of the Board of Directors. Mr. Mayron's appointment follows shareholder approval and submission of his formal Director Eligibility Declaration in accordance with the Israeli Companies Law.</description>
</item>
<item>
<title>Matricelf to Attend The Digital Spine & Pain Neuroscience Summit 2026 in Phoenix, Arizona</title>
<link>https://6ix.com/company/matricelf-ltd/news/matricelf-to-attend-the-digital-spine-and-pain-neuroscience-summit-2026-in-phoenix-arizona</link>
<guid isPermaLink="true">https://6ix.com/company/matricelf-ltd/news/matricelf-to-attend-the-digital-spine-and-pain-neuroscience-summit-2026-in-phoenix-arizona</guid>
<pubDate>Thu, 26 Feb 2026 12:30:00 GMT</pubDate>
<description>Matricelf Ltd. (TASE: MTLF), a regenerative medicine company advancing personalized curative treatments for spinal cord injury, announced that it will attend the Digital Spine & Pain Neuroscience Summit 2026 (DSPN Spine Summit) being held in Phoenix, AZ between the February 26th to March 1st. The Summit is one of the premier global gatherings for clinicians, researchers, industry leaders, and innovators focused on spine care, neuroscience, and advanced therapeutic technologies.</description>
</item>
<item>
<title>Cellino and Matricelf Announce Global Collaboration to Scale Personalized Spinal Cord Injury Treatments</title>
<link>https://6ix.com/company/matricelf-ltd/news/cellino-matricelf-announce-global-collaboration-120000765</link>
<guid isPermaLink="true">https://6ix.com/company/matricelf-ltd/news/cellino-matricelf-announce-global-collaboration-120000765</guid>
<pubDate>Tue, 11 Mar 2025 12:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., March 11, 2025--Cellino and Matricelf Announce Global Collaboration to Scale Personalized Spinal Cord Injury Treatments</description>
</item>
</channel>
</rss>